These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27091466)

  • 21. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
    Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.
    Basu NN; Ingham S; Hodson J; Lalloo F; Bulman M; Howell A; Evans DG
    Fam Cancer; 2015 Dec; 14(4):531-8. PubMed ID: 26239694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer.
    S Chapman J; Roddy E; Panighetti A; Hwang S; Crawford B; Powell B; Chen LM
    Clin Breast Cancer; 2016 Dec; 16(6):494-499. PubMed ID: 27495996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer worry among Norwegian male BRCA1/2 mutation carriers.
    Strømsvik N; Råheim M; Gjengedal E
    Fam Cancer; 2011 Sep; 10(3):597-603. PubMed ID: 21603983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing.
    Lodder L; Frets PG; Trijsburg RW; Tibben A; Meijers-Heijboer EJ; Duivenvoorden HJ; Wagner A; van Der Meer CA; Devilee P; Cornelisse CJ; Niermeijer MF
    Eur J Hum Genet; 2001 Jul; 9(7):492-500. PubMed ID: 11464240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.
    Nielsen HR; Nilbert M; Petersen J; Ladelund S; Thomassen M; Pedersen IS; Hansen TV; Skytte AB; Borg Å; Therkildsen C
    Fam Cancer; 2016 Oct; 15(4):507-12. PubMed ID: 26833046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
    Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
    Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.
    Jarhelle E; Riise Stensland HM; Mæhle L; Van Ghelue M
    Fam Cancer; 2017 Jan; 16(1):1-16. PubMed ID: 27495310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study on the psychosocial aspects of risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers in Japan: a preliminary report.
    Shigehiro M; Kita M; Takeuchi S; Ashihara Y; Arai M; Okamura H
    Jpn J Clin Oncol; 2016 Mar; 46(3):254-9. PubMed ID: 26685323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
    Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
    Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
    Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
    Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers--implications for oncogenetics practice.
    Bancroft EK; Locke I; Ardern-Jones A; D'Mello L; McReynolds K; Lennard F; Barbachano Y; Barwell J; Walker L; Mitchell G; Dorkins H; Cummings C; Paterson J; Kote-Jarai Z; Mitra A; Jhavar S; Thomas S; Houlston R; Shanley S; Eeles RA
    J Med Genet; 2010 Jul; 47(7):486-91. PubMed ID: 20472659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylactic mastectomy or screening in women suspected to have the BRCA1/2 mutation: a prospective pilot study of women's treatment choices and medical and decision-analytic recommendations.
    Unic I; Verhoef LC; Stalmeier PF; van Daal WA
    Med Decis Making; 2000; 20(3):251-62. PubMed ID: 10929847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.
    Cini G; Mezzavilla M; Della Puppa L; Cupelli E; Fornasin A; D'Elia AV; Dolcetti R; Damante G; Bertok S; Miolo G; Maestro R; de Paoli P; Amoroso A; Viel A
    BMC Med Genet; 2016 Feb; 17():11. PubMed ID: 26852130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: patients' and professionals' perspectives.
    Arts-de Jong M; Harmsen MG; Hoogerbrugge N; Massuger LF; Hermens RP; de Hullu JA
    Gynecol Oncol; 2015 Feb; 136(2):305-10. PubMed ID: 25560807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Report of Endometrial Cancer in Australian BRCA1 and BRCA2 mutation-positive Families.
    Duffy DL; Antill YC; Stewart CJ; Young JP; ; Spurdle AB
    Twin Res Hum Genet; 2011 Apr; 14(2):111-8. PubMed ID: 21425892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
    Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA;
    J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parental Decision Making Regarding the Disclosure or Nondisclosure of a Mutation-Positive BRCA1/2 Test Result to Minors.
    Seenandan-Sookdeo KA; Hack TF; Lobchuk M; Murphy L; Marles S
    Oncol Nurs Forum; 2016 May; 43(3):330-41. PubMed ID: 27105194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.